Financial Review: Sera Prognostics (NASDAQ:SERA) and Neuphoria Therapeutics (NASDAQ:NEUP)

Neuphoria Therapeutics (NASDAQ:NEUP) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Neuphoria Therapeutics and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Volatility and Risk

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Earnings & Valuation

This table compares Neuphoria Therapeutics and Sera Prognostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	15.21	-$13.45 million	($6.22)	-0.53
Sera Prognostics	$70,000.00	1,160.93	-$31.93 million	($0.67)	-3.07

Neuphoria Therapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Neuphoria Therapeutics and Sera Prognostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Sera Prognostics	1	0	1	1	2.67

Neuphoria Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 112.12%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 166.99%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Neuphoria Therapeutics.

Summary

Sera Prognostics beats Neuphoria Therapeutics on 9 of the 15 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.